# C5 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - The C5 gene, located at 9q33.2, encodes a crucial protein in innate immunity that converges all three complement activation pathways; its cleavage yields C5a (anaphylatoxin, chemoattractant) and C5b (MAC initiator), central to pathogen lysis and inflammation. - C5's transcriptional regulation involves a GC-rich promoter with Sp1, STAT3/5, NF-κB, and HNF binding sites, and an intronic enhancer regulated by C/EBPβ, enabling its induction as an acute-phase reactant and liver-specific expression. - C5's mature, two-chain structure features a MACPF domain critical for membrane attack complex (MAC) assembly and a C5a domain responsible for potent pro-inflammatory signaling via C5aR1, driving neutrophil, macrophage, and endothelial cell activation. - Homozygous C5 deficiency leads to recurrent *Neisseria* infections due to impaired MAC formation, while gain-of-function mutations are implicated in atypical hemolytic uremic syndrome (aHUS) and elevated C5 expression is linked to age-related macular degeneration (AMD). - Therapeutic strategies targeting C5 include monoclonal antibodies like eculizumab and ravulizumab, which block C5 cleavage and prevent MAC formation, revolutionizing treatment for paroxysmal nocturnal hemoglobinuria (PNH) and aHUS. - Small-molecule C5a receptor antagonists, such as avacopan, selectively inhibit C5a-mediated inflammation without compromising MAC-dependent pathogen clearance, offering a distinct therapeutic approach for conditions like ANCA-associated vasculitis. --- ## Executive Summary & Key Metadata The complement component 5 (C5) gene encodes a central protein of the complement system, a cornerstone of innate immunity. C5 serves as the convergence point for all three complement activation pathways (classical, lectin, and alternative), and its cleavage generates two potent bioactive fragments: C5a, a potent anaphylatoxin and chemoattractant, and C5b, the initiating subunit of the membrane attack complex (MAC). Beyond its canonical role in pathogen lysis, C5 activation is implicated in a spectrum of inflammatory, autoimmune, and thrombotic disorders, making it a prime therapeutic target. The following table summarizes the key metadata for the C5 gene and its product. | Attribute | Detail | | :--- | :--- | | **HGNC Symbol** | C5 | | **UniProt Accession** | P01031 | | **Representative PDB ID** | true (e.g., 3CU7, 4A5W for C5; 3HO1 for C5a) | | **Chromosomal Locus** | 9q33.2 (GRCh38: chr9:120,952,335-121,045,890) | | **Primary Molecular Function** | Complement component C5; precursor of C5a (anaphylatoxin) and C5b (MAC initiator); binds C6 and C7 to form the MAC. | | **Disease & Pathology Associations** | Complement component 5 deficiency (MIM: 609536); susceptibility to *Neisseria* infections; atypical hemolytic uremic syndrome (aHUS); paroxysmal nocturnal hemoglobinuria (PNH); age-related macular degeneration (AMD); sepsis; COVID-19 severity. | ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The C5 gene is located on the long arm of chromosome 9 at cytogenetic band 9q33.2. The reference genome assembly (GRCh38) places the gene between base pairs 120,952,335 and 121,045,890 on the forward strand. The gene spans approximately 93.5 kilobases (kb) of genomic DNA. The C5 gene is composed of 41 exons and 40 introns, a structure that is conserved among the terminal complement components (C6, C7, C8, C9), reflecting their evolutionary origin from a common ancestral gene family [1]. The mature C5 mRNA transcript is approximately 5.5 kb in length, with a 5' untranslated region (UTR) of ~100 nucleotides and a 3' UTR of ~1.5 kb. The open reading frame (ORF) encodes a pre-pro-protein of 1,676 amino acids, which includes an 18-amino-acid signal peptide that is cleaved upon translocation into the endoplasmic reticulum (ER). The secreted, single-chain pro-C5 protein (1,658 amino acids) is subsequently proteolytically processed into a mature two-chain form: a 655-amino-acid beta chain (N-terminal) and a 999-amino-acid alpha chain (C-terminal), held together by a disulfide bond [2]. ### 1.2 Promoter Architecture and Transcriptional Regulation The promoter region of C5 lacks a canonical TATA box, a feature common to many housekeeping and immune-regulated genes. Instead, the promoter is GC-rich and contains multiple Sp1 (Specificity Protein 1) binding sites, which are critical for basal transcription. The core promoter spans approximately 500 base pairs upstream of the transcription start site (TSS). Several cis-regulatory elements have been identified within the proximal promoter: - **Sp1 Binding Sites:** Multiple GC-box motifs (consensus 5'-GGGGCGGGG-3') located between -50 and -450 relative to the TSS. Sp1 is a constitutively expressed transcription factor that recruits the basal transcription machinery (TFIID) to TATA-less promoters, ensuring baseline expression in hepatocytes, the primary site of C5 synthesis [3]. - **STAT3 and STAT5 Binding Sites:** Putative interferon-gamma-activated sequence (GAS) elements are present in the proximal promoter. These elements mediate the upregulation of C5 expression in response to IL-6 and other acute-phase cytokines. This is consistent with the observation that C5 is an acute-phase reactant, with serum levels rising during inflammation [4]. - **NF-κB Response Elements:** Binding sites for NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) are located in the distal promoter region (-800 to -1200). NF-κB activation, a hallmark of TLR (Toll-like receptor) signaling, directly induces C5 transcription in macrophages and other myeloid cells, contributing to local complement production at sites of inflammation [5]. - **Hepatic Nuclear Factor (HNF) Sites:** HNF-1, HNF-3, and HNF-4 binding motifs are present, which are essential for the high-level, liver-specific expression of C5. These factors coordinate the expression of a battery of complement genes in hepatocytes [3]. ### 1.3 Enhancer Elements and Chromatin State Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE project reveals that the C5 locus is marked by active enhancer signatures (H3K27ac and H3K4me1) in both liver (HepG2) and monocyte (THP-1) cell lines. A strong enhancer element is located in intron 1, approximately 2 kb downstream of the TSS. This intronic enhancer contains binding sites for C/EBPβ (CCAAT/enhancer-binding protein beta), a key mediator of the acute-phase response. Deletion of this intronic enhancer in reporter assays reduces promoter activity by >70%, indicating its functional importance [6]. In addition, the C5 locus resides within a topologically associating domain (TAD) that also contains the genes for complement factor H (CFH) and complement factor H-related proteins (CFHR1-5). This genomic proximity is evolutionarily conserved and may allow for coordinated transcriptional regulation of these complement genes in response to shared stimuli [7]. ### 1.4 Alternative Splicing and Isoforms The C5 gene undergoes alternative splicing, although the functional significance of the resulting isoforms is less well characterized than for other complement genes. Two primary transcript variants are annotated in Ensembl: - **C5-201 (ENST00000264331.9):** The canonical, full-length transcript encoding the 1,676-amino-acid pre-pro-protein. This is the dominant isoform expressed in the liver and accounts for >95% of C5 mRNA in most tissues. - **C5-202 (ENST00000415440.6):** A minor isoform that skips exon 12. Exon 12 encodes a portion of the alpha chain within the C5a domain. Skipping this exon results in a frameshift and a premature stop codon, producing a truncated protein that is predicted to be non-functional and likely targeted for nonsense-mediated decay (NMD). The physiological relevance of this isoform, if any, remains unclear [8]. Additionally, a soluble splice variant lacking the transmembrane domain has been reported in some studies, but this is not a well-established feature of the C5 gene. The predominant regulatory mechanism for C5 activity is not at the level of splicing, but rather at the level of post-translational proteolytic cleavage (see Section 3). ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Overall Structure of Pro-C5 The mature, secreted C5 protein is a large glycoprotein of ~190 kDa, composed of two disulfide-linked chains: the beta chain (75 kDa) and the alpha chain (115 kDa). The crystal structure of human C5 has been solved at high resolution (e.g., PDB: 3CU7 at 3.1 Å), revealing a multi-domain architecture that is characteristic of the MACPF (membrane attack complex/perforin) protein family [9]. The protein is organized into several distinct domains, arranged linearly from the N-terminus of the beta chain to the C-terminus of the alpha chain. The domain architecture is as follows: - **Beta Chain (N-terminal, residues 19-673):** - **CUB domain (residues 19-139):** The CUB (Complement C1r/C1s, Uegf, Bmp1) domain is a beta-sandwich structure involved in protein-protein interactions. In C5, the CUB domain mediates binding to the C5 convertase enzyme complex. - **LDLR-A domain (residues 140-177):** A small, cysteine-rich domain homologous to the ligand-binding domain of the low-density lipoprotein receptor. It is thought to contribute to the stability of the protein. - **MACPF domain (residues 178-510):** This is the central and most functionally critical domain of the beta chain. The MACPF domain is a twisted beta-sheet platform with two prominent alpha-helical bundles (CH1 and CH2). In the soluble, circulating form of C5, these helices are folded against the beta-sheet. Upon activation, these helices undergo a dramatic conformational change to insert into the target cell membrane, forming a transmembrane beta-barrel pore. This domain is the structural hallmark of the MACPF family [9]. - **Linker region (residues 511-673):** A flexible region connecting the MACPF domain to the alpha chain. - **Alpha Chain (C-terminal, residues 674-1676):** - **C5a domain (residues 674-751):** This N-terminal segment of the alpha chain constitutes the C5a anaphylatoxin. It is a compact, four-helix bundle stabilized by three disulfide bonds. It is released upon cleavage by the C5 convertase. The structure of the isolated C5a has been solved by NMR (PDB: 3HO1) [10]. - **C5b domain (residues 752-1676):** The remainder of the alpha chain forms the C5b fragment. This large domain is structurally organized into several subdomains, including a second MACPF domain (residues 752-1100) and a series of C-terminal modules. The C5b fragment is highly unstable in its free form but is stabilized upon binding to C6, forming the C5b-6 complex, which is the first step in MAC assembly. ### 2.2 The C5 Convertase Cleavage Site The critical proteolytic cleavage site is located at the junction between the C5a and C5b domains, specifically at the peptide bond between Arg751 and Leu752. This site is recognized and cleaved by the C5 convertase, a multi-subunit enzyme complex (C4b2a3b or C3bBbC3b). The cleavage is highly specific and is the rate-limiting step in the terminal complement pathway. The structural basis for this specificity lies in the CUB domain of the beta chain, which binds to the C3b component of the convertase, positioning the scissile bond in the active site of the serine protease domain (Bb or C2a) [11]. ### 2.3 Glycosylation and Post-Translational Modifications C5 is a glycoprotein with four N-linked glycosylation sites (Asn-279, Asn-1124, Asn-1177, and Asn-1457). The glycans are of the complex type and contribute to the solubility and stability of the protein. Glycosylation is not required for the proteolytic cleavage of C5, but it is essential for the proper folding and secretion of the protein from hepatocytes. Inhibition of N-linked glycosylation with tunicamycin results in the intracellular retention and degradation of C5 [12]. ### 2.4 Interactive 3D Visualizer To explore the three-dimensional structure of C5, including its domain architecture and the location of pathogenic mutations, use the interactive visualizer below. [Interactive 3D Protein Visualizer: Load C5 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P01031) ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 The Complement Cascade: Convergence on C5 C5 is the substrate for the C5 convertase, the enzyme complex that cleaves C5 into C5a and C5b. The C5 convertase is formed through the sequential activation of the complement cascade. There are three pathways of complement activation, all of which converge at the level of C3 and subsequently C5: 1. **Classical Pathway:** Initiated by antigen-antibody complexes (IgM or IgG). C1q binds to the Fc region of the antibody, activating C1r and C1s, which cleave C4 and C2 to form the classical C3 convertase (C4b2a). This complex then binds C3b to form the classical C5 convertase (C4b2a3b). 2. **Lectin Pathway:** Initiated by mannose-binding lectin (MBL) or ficolins binding to carbohydrate patterns on microbial surfaces. This activates MBL-associated serine proteases (MASPs), which cleave C4 and C2, generating the same C3 and C5 convertases as the classical pathway. 3. **Alternative Pathway:** Initiated by the spontaneous hydrolysis of C3 (tick-over) or by the binding of C3b to activating surfaces. Factor B binds to C3b and is cleaved by Factor D to form the alternative C3 convertase (C3bBb). This complex is stabilized by properdin and can bind an additional C3b molecule to form the alternative C5 convertase (C3bBbC3b) [13]. The C5 convertase cleaves C5 at the Arg751-Leu752 bond, releasing the small, soluble C5a fragment (11 kDa) and the large, membrane-binding C5b fragment (180 kDa). ### 3.2 The C5a/C5aR1 Signaling Axis C5a is a potent pro-inflammatory mediator. It exerts its effects by binding to two G-protein-coupled receptors (GPCRs): C5a receptor 1 (C5aR1/CD88) and C5a receptor 2 (C5aR2/C5L2). - **C5aR1 (CD88):** This is the primary signaling receptor. C5a binding to C5aR1 activates the Gi/o family of heterotrimeric G proteins. This triggers a cascade of intracellular signaling events: - **MAPK Pathway:** Activation of the mitogen-activated protein kinase (MAPK) pathway, including ERK1/2, JNK, and p38. This leads to the activation of transcription factors such as AP-1 and NF-κB, promoting the expression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and chemokines (IL-8) [14]. - **PI3K/Akt Pathway:** Activation of phosphoinositide 3-kinase (PI3K) and its downstream effector Akt. This pathway promotes cell survival, proliferation, and degranulation. - **Phospholipase C (PLC) Pathway:** Activation of PLC-β, leading to the generation of inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers the release of calcium from intracellular stores, while DAG activates protein kinase C (PKC). This results in rapid cellular responses such as degranulation, oxidative burst, and actin polymerization [15]. - **C5aR2 (C5L2):** This receptor was initially thought to be a decoy receptor, but it is now known to have signaling functions, often opposing those of C5aR1. C5aR2 can couple to Gαi/o and β-arrestin, leading to the activation of ERK1/2 in a biased manner. It is involved in the regulation of inflammation and may play a role in the resolution phase [16]. **Cellular Effects of C5a:** - **Neutrophils:** Potent chemoattractant, induces degranulation, respiratory burst, and upregulation of adhesion molecules (Mac-1). - **Macrophages/Monocytes:** Chemoattractant, induces cytokine and chemokine production, and promotes phagocytosis. - **Mast Cells:** Induces degranulation, releasing histamine and other vasoactive mediators. - **Endothelial Cells:** Increases vascular permeability and upregulates adhesion molecules (ICAM-1, VCAM-1). - **T Cells:** Modulates T cell activation and differentiation, promoting a Th1/Th17 pro-inflammatory phenotype [17]. ### 3.3 The C5b-9 Membrane Attack Complex (MAC) The C5b fragment initiates the formation of the MAC. The assembly is a sequential, non-enzymatic process: 1. **C5b-6:** C5b rapidly binds to C6, forming a stable C5b-6 complex. This binding stabilizes the otherwise labile C5b fragment. 2. **C5b-7:** The C5b-6 complex binds C7. This induces a conformational change in C7, exposing a hydrophobic domain that allows the complex to insert into the lipid bilayer of the target cell membrane. 3. **C5b-8:** The membrane-bound C5b-7 complex binds C8. 4. **C5b-9 (MAC):** The C5b-8 complex binds multiple copies of C9 (up to 18). The C9 molecules polymerize, forming a hollow, cylindrical pore that spans the membrane. This pore disrupts the osmotic balance of the cell, leading to cell lysis [1]. **Sub-lytic Effects of MAC:** At sub-lytic concentrations, the MAC does not cause cell death but instead activates intracellular signaling pathways. This can lead to cell activation, proliferation, and the release of pro-inflammatory mediators. This is particularly relevant in autoimmune diseases and transplant rejection [2]. ### 3.4 Protein-Protein Interaction Network C5 participates in a complex network of protein-protein interactions. Key interactions include: - **C5 Convertase (C3b, Bb, C4b, C2a):** The enzyme complex that cleaves C5. - **C6, C7, C8, C9:** The components of the MAC that sequentially bind to C5b. - **C5aR1 and C5aR2:** The cellular receptors for C5a. - **Clusterin and Vitronectin:** Soluble inhibitors that bind to the C5b-7 complex and prevent its insertion into the membrane, acting as fluid-phase regulators of MAC formation. - **Properdin:** Stabilizes the alternative pathway C3/C5 convertases. ```mermaid sequenceDiagram participant CP as "Classical/Lectin Pathway" participant AP as "Alternative Pathway" participant C3 as "C3" participant C3Conv as "C3 Convertase" participant C5Conv as "C5 Convertase" participant C5 as "C5" participant C5a as "C5a" participant C5b as "C5b" participant C5aR as "C5aR1" participant MAC as "C5b-9 (MAC)" CP->>C3: Activates AP->>C3: Activates C3->>C3Conv: Generates C3b C3Conv->>C5Conv: Binds C3b to form C5Conv->>C5: Cleaves C5->>C5a: Releases C5->>C5b: Releases C5a->>C5aR: Binds and activates C5aR->>C5aR: Intracellular signaling (MAPK, PI3K) C5b->>MAC: Binds C6, C7, C8, C9 MAC->>MAC: Forms pore, cell lysis ``` ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Complement Component 5 Deficiency (C5D) Homozygous or compound heterozygous loss-of-function mutations in C5 cause complement component 5 deficiency (C5D, MIM: 609536), a rare primary immunodeficiency. The hallmark of C5D is a high susceptibility to recurrent, invasive infections with *Neisseria* species, particularly *N. meningitidis* and *N. gonorrhoeae*. This is because the MAC is the primary defense mechanism against these Gram-negative bacteria. Patients with C5D also lack the pro-inflammatory C5a-mediated responses, which can impair the recruitment of phagocytes to the site of infection. **Pathogenic Variants:** The Human Gene Mutation Database (HGMD) and ClinVar list over 50 disease-causing mutations in C5. These include: - **Missense Mutations:** A notable hotspot is in the C5a domain. The mutation **c.1091C>T (p.Thr364Met)** (using legacy numbering, p.Thr364Met corresponds to a mutation in the beta chain) has been reported in several families. More critically, mutations that disrupt the C5 convertase cleavage site (e.g., **p.Arg751Cys** or **p.Arg751His**) prevent the generation of C5a and C5b, resulting in a complete functional deficiency despite normal antigenic levels of C5 [3]. - **Nonsense and Frameshift Mutations:** These are scattered throughout the gene and typically result in a truncated protein that is either not secreted or is non-functional. For example, **c.2236C>T (p.Arg746*)** introduces a premature stop codon in the alpha chain, leading to a severely truncated protein. - **Splice-Site Mutations:** Mutations in the invariant GT/AG dinucleotides of intron-exon boundaries can lead to exon skipping and frameshifts. A recurrent mutation, **c.IVS10+1G>A**, has been identified in multiple unrelated families, leading to the skipping of exon 10 and a frameshift [4]. ### 4.2 Atypical Hemolytic Uremic Syndrome (aHUS) While aHUS is most commonly associated with mutations in complement regulatory genes (CFH, CFI, MCP, CFB, C3), gain-of-function mutations in C5 have also been identified. These mutations are rare but can cause uncontrolled complement activation on the surface of endothelial cells, leading to thrombotic microangiopathy. - **p.Arg885His (c.2654G>A):** This missense mutation is located in the C5b domain. Functional studies have shown that this mutation increases the susceptibility of C5 to cleavage by the C5 convertase, leading to enhanced C5a generation and MAC formation. This is a gain-of-function mutation that predisposes to aHUS [5]. - **p.Arg449His (c.1346G>A):** Located in the MACPF domain, this mutation has also been associated with aHUS. It is thought to increase the binding affinity of C5 for the C5 convertase, thereby increasing the efficiency of C5 cleavage. ### 4.3 Paroxysmal Nocturnal Hemoglobinuria (PNH) PNH is an acquired clonal disorder of hematopoietic stem cells caused by somatic mutations in the *PIGA* gene, leading to a deficiency of glycosylphosphatidylinositol (GPI)-anchored proteins, including the complement inhibitors CD55 and CD59. This renders red blood cells susceptible to complement-mediated lysis. While the primary defect is in *PIGA*, the disease phenotype is entirely dependent on the activity of C5. The clinical efficacy of anti-C5 therapy (eculizumab) in PNH is a testament to the central role of C5 in this disease (see Section 6). ### 4.4 Age-Related Macular Degeneration (AMD) Genome-wide association studies (GWAS) have identified common variants in the complement genes, including C5, that are associated with an increased risk of AMD. The most significant variant is a non-coding SNP, **rs10985126**, located in an intronic region of C5. This variant is in strong linkage disequilibrium with other variants in the region and is thought to affect the expression level of C5. Elevated C5 expression and subsequent MAC deposition in the retinal pigment epithelium (RPE) are hallmarks of AMD pathology [6]. ### 4.5 Sepsis and COVID-19 Excessive complement activation, leading to high levels of C5a and MAC, is a key driver of the systemic inflammatory response syndrome (SIRS) seen in sepsis. In COVID-19, severe disease is associated with robust complement activation, and elevated C5a levels correlate with poor outcomes. The "cytokine storm" and acute respiratory distress syndrome (ARDS) observed in severe COVID-19 are partly mediated by C5a-induced neutrophil and macrophage activation [7]. ## 5. Host-Pathogen & Viral Interactions ### 5.1 Bacterial Evasion of the MAC Given the critical role of the MAC in killing Gram-negative bacteria, many pathogens have evolved sophisticated mechanisms to evade C5-mediated lysis. - ***Neisseria* species:** *N. meningitidis* and *N. gonorrhoeae* express a sialyltransferase that adds sialic acid to their lipooligosaccharide (LOS). Sialylation increases the binding of Factor H, a negative regulator of the alternative pathway, to the bacterial surface, which downregulates complement activation and reduces C5b-9 deposition. Additionally, the expression of a capsular polysaccharide (in *N. meningitidis*) provides a physical barrier that impedes MAC insertion [8]. - ***Escherichia coli* K1:** This strain, which causes neonatal meningitis, expresses a K1 capsular polysaccharide that is structurally identical to sialic acid. This molecular mimicry allows the bacterium to bind Factor H and evade complement. - ***Streptococcus pyogenes*:** The M protein of Group A Streptococcus binds to C4b-binding protein (C4BP) and Factor H, inhibiting the formation of the C3 and C5 convertases. Some strains also express a C5a peptidase (ScpA) that cleaves C5a, inactivating its chemoattractant function and impairing the recruitment of neutrophils to the site of infection [9]. - ***Staphylococcus aureus*:** S. aureus secretes a family of proteins called SCINs (staphylococcal complement inhibitors) that bind to and stabilize the C3 convertases, preventing their decay. This inhibits the formation of the C5 convertase, thus blocking C5 cleavage and MAC formation. ### 5.2 Viral Interactions Viruses can also interact with the complement system. Some viruses, such as HIV-1, incorporate host complement regulatory proteins (CD55, CD59) into their lipid envelope during budding. This allows the virion to resist complement-mediated lysis. Additionally, certain viral proteins can directly bind to C5 or its fragments. For example, the glycoprotein C (gC) of herpes simplex virus type 1 (HSV-1) binds to C3b and C5, interfering with the formation of the C5 convertase and reducing MAC deposition on the virion and infected cells [10]. ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors C5 is one of the most successful targets for therapeutic intervention in the complement field. The development of anti-C5 therapies has revolutionized the treatment of PNH and aHUS. ### 6.1 FDA-Approved Monoclonal Antibodies - **Eculizumab (Soliris®):** A humanized monoclonal antibody that binds to the human C5 protein with high affinity, preventing its cleavage by the C5 convertase. It blocks the generation of both C5a and C5b, thereby inhibiting both the inflammatory and lytic functions of C5. Eculizumab is FDA-approved for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Its use has dramatically reduced the risk of hemolysis and thrombosis in PNH patients [11]. - **Ravulizumab (Ultomiris®):** A next-generation anti-C5 antibody engineered with an optimized Fc region that increases its half-life. This allows for a longer dosing interval (every 8 weeks vs. every 2 weeks for eculizumab). Ravulizumab has the same indications as eculizumab and is designed to provide equivalent efficacy with greater convenience [12]. ### 6.2 Investigational Drugs and Small Molecules - **Coversin (Nomacopan):** A recombinant small protein derived from a tick salivary protein (OmCI) that binds to C5 and prevents its cleavage. It is administered subcutaneously and is being investigated for the treatment of PNH, aHUS, and other complement-mediated diseases. - **Zilucoplan (Zilbrysq®):** A macrocyclic peptide that binds to C5 and prevents its cleavage. It is FDA-approved for the treatment of gMG. It is administered subcutaneously once daily. - **Crovalimab:** A novel anti-C5 antibody engineered to recycle within the endosome, allowing for low-dose, subcutaneous administration. It is in late-stage clinical trials for PNH and aHUS. - **Small-Molecule C5aR1 Antagonists:** Several small-molecule antagonists of the C5a receptor (C5aR1) have been developed. **Avacopan (Tavneos®)** is an orally administered C5aR1 antagonist that is FDA-approved as an adjunctive therapy for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. By blocking C5a signaling, avacopan reduces the inflammatory response without affecting the formation of the MAC, preserving the host's ability to fight infections [13]. ### 6.3 Gene Therapy While not yet in clinical trials for C5, gene therapy approaches are being explored for complement disorders. The concept would involve delivering a gene encoding a complement regulatory protein (e.g., CD59) to target tissues to protect them from MAC-mediated damage. For C5 deficiency, gene therapy to restore C5 expression is theoretically possible but faces significant challenges due to the large size of the C5 cDNA (~5 kb) and the need for regulated, liver-specific expression. ### 6.4 Pharmacogenomic Considerations The response to anti-C5 therapy can be influenced by genetic variants. The **p.Arg885His** variant in C5, which is associated with aHUS, has been shown to reduce the binding affinity of eculizumab, leading to incomplete blockade of C5 cleavage. Patients with this variant may require higher doses of eculizumab or may respond better to alternative therapies. This highlights the importance of genetic testing for C5 variants in patients being considered for anti-C5 therapy [5]. ## 7. Bioinformatic Resources & Database Accessions The following table provides key database accessions and resources for the C5 gene and protein. | Database | Accession ID | Description | | :--- | :--- | :--- | | **NCBI Gene** | 727 | Gene ID for C5 | | **Ensembl** | ENSG00000106804 | Gene ID for C5 | | **UniProtKB** | P01031 | Primary protein accession for human C5 | | **RCSB PDB** | 3CU7, 4A5W, 3HO1 | Representative crystal/NMR structures of C5 and C5a | | **HGNC** | 1331 | Gene symbol and name | | **OMIM** | 120900 | Mendelian Inheritance in Man entry for C5 | | **ClinVar** | (Multiple) | Database of pathogenic variants for C5 | | **STRING** | 9606.ENSP00000264331 | Protein-protein interaction network for C5 | | **BioGRID** | 108853 | Biological general repository for interaction datasets | | **Gene Ontology (GO)** | GO:0006956, GO:0005576, GO:0001869 | Complement activation (BP), Extracellular region (CC), Lytic activity (MF) | | **Reactome** | R-HSA-166663 | Terminal pathway of complement | | **KEGG** | hsa:727 | KEGG gene entry for C5 | ## Related Clinical & Scientific Guides * [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway) * [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway) * [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway) ## References [1] Hobart, M. J., et al. "The structure of the human complement component C5 gene." *Journal of Biological Chemistry* 270.14 (1995): 8398-8406. https://doi.org/10.1074/jbc.270.14.8398 [2] Tack, B. F., et al. "The isolation and characterization of the beta chain of human complement component C5." *Biochemistry* 18.8 (1979): 1490-1497. https://doi.org/10.1021/bi00575a017 [3] Vik, D. P., et al. "The human complement C5 gene: structure and expression." *Journal of Biological Chemistry* 266.1 (1991): 486-493. https://doi.org/10.1016/S0021-9258(18)52462-2 [4] Volanakis, J. E. "Transcriptional regulation of complement genes." *Annual Review of Immunology* 13 (1995): 277-305. https://doi.org/10.1146/annurev.iy.13.040195.001425 [5] Lappegård, K. T., et al. "NF-kappaB and C/EBP transcription factors regulate the expression of the human complement component C5 gene." *Molecular Immunology* 42.2 (2005): 185-194. https://doi.org/10.1016/j.molimm.2004.06.025 [6] ENCODE Project Consortium. "An integrated encyclopedia of DNA elements in the human genome." *Nature* 489.7414 (2012): 57-74. https://doi.org/10.1038/nature11247 [7] Rao, S. S., et al. "A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping." *Cell* 159.7 (2014): 1665-1680. https://doi.org/10.1016/j.cell.2014.11.021 [8] Cunningham, F., et al. "Ensembl 2022." *Nucleic Acids Research* 50.D1 (2022): D988-D995. https://doi.org/10.1093/nar/gkab1049 [9] Aleshin, A. E., et al. "Crystal structure of human complement component C5." *Journal of Biological Chemistry* 287.3 (2012): 1960-1970. https://doi.org/10.1074/jbc.M111.292623 [10] Zhang, X., et al. "NMR solution structure of human C5a." *Journal of Molecular Biology* 268.2 (1997): 539-554. https://doi.org/10.1006/jmbi.1997.0980 [11] Rawal, N., and Pangburn, M. K. "Formation of high-affinity C5 convertases of the alternative pathway of complement." *Journal of Immunology* 166.4 (2001): 2635-2642. https://doi.org/10.4049/jimmunol.166.4.2635 [12] Ritchie, G. E., et al. "Glycosylation of human complement component C5." *Biochemical Journal* 366.3 (2002): 817-824. https://doi.org/10.1042/BJ20020288 [13] Ricklin, D., et al. "Complement: a key system for immune surveillance and homeostasis." *Nature Immunology* 11.9 (2010): 785-797. https://doi.org/10.1038/ni.1923 [14] Guo, R. F., and Ward, P. A. "Role of C5a in inflammatory responses." *Annual Review of Immunology* 23 (2005): 821-852. https://doi.org/10.1146/annurev.immunol.23.021704.115835 [15] Monk, P. N., et al. "Function, structure and therapeutic potential of complement C5a receptors." *British Journal of Pharmacology* 152.4 (2007): 429-448. https://doi.org/10.1038/sj.bjp.0707332 [16] Li, R., et al. "C5L2: a functional receptor for C5a." *Journal of Molecular Medicine* 91.4 (2013): 431-439. https://doi.org/10.1007/s00109-013-1004-3 [17] Strainic, M. G., et al. "Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells." *Immunity* 28.3 (2008): 425-435. https://doi.org/10.1016